Morgan Stanley’s ALX Oncology ALXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $48.8K | Sell |
117,465
-240,995
| -67% | -$100K | ﹤0.01% | 6367 |
|
|
2025
Q1 | $223K | Sell |
358,460
-2,140,642
| -86% | -$1.33M | ﹤0.01% | 5687 |
|
|
2024
Q4 | $4.17M | Buy |
2,499,102
+2,178,330
| +679% | +$3.64M | ﹤0.01% | 4148 |
|
|
2024
Q3 | $584K | Sell |
320,772
-352,586
| -52% | -$642K | ﹤0.01% | 5329 |
|
|
2024
Q2 | $4.06M | Buy |
673,358
+330,221
| +96% | +$1.99M | ﹤0.01% | 4052 |
|
|
2024
Q1 | $3.83M | Sell |
343,137
-484,449
| -59% | -$5.4M | ﹤0.01% | 4128 |
|
|
2023
Q4 | $12.3M | Buy |
827,586
+494,103
| +148% | +$7.36M | ﹤0.01% | 3747 |
|
|
2023
Q3 | $1.6M | Buy |
333,483
+90,637
| +37% | +$435K | ﹤0.01% | 4523 |
|
|
2023
Q2 | $1.82M | Sell |
242,846
-71,340
| -23% | -$536K | ﹤0.01% | 4485 |
|
|
2023
Q1 | $1.42M | Sell |
314,186
-172,132
| -35% | -$778K | ﹤0.01% | 4654 |
|
|
2022
Q4 | $5.48M | Buy |
486,318
+89,681
| +23% | +$1.01M | ﹤0.01% | 3674 |
|
|
2022
Q3 | $3.8M | Sell |
396,637
-47,298
| -11% | -$453K | ﹤0.01% | 3921 |
|
|
2022
Q2 | $3.59M | Buy |
443,935
+59,417
| +15% | +$481K | ﹤0.01% | 4055 |
|
|
2022
Q1 | $6.5M | Buy |
384,518
+129,818
| +51% | +$2.19M | ﹤0.01% | 3394 |
|
|
2021
Q4 | $5.47M | Buy |
254,700
+173,280
| +213% | +$3.72M | ﹤0.01% | 3628 |
|
|
2021
Q3 | $6.01M | Sell |
81,420
-19,589
| -19% | -$1.45M | ﹤0.01% | 3477 |
|
|
2021
Q2 | $5.52M | Buy |
101,009
+96,452
| +2,117% | +$5.27M | ﹤0.01% | 3675 |
|
|
2021
Q1 | $336K | Sell |
4,557
-8,007
| -64% | -$590K | ﹤0.01% | 5371 |
|
|
2020
Q4 | $1.08M | Buy |
12,564
+10,665
| +562% | +$919K | ﹤0.01% | 4618 |
|
|
2020
Q3 | $72K | Buy |
+1,899
| New | +$72K | ﹤0.01% | 5567 |
|